Regulatory News for April 24, 2024

Increased Biomarker Uptake Needed to Further Realize Potential of Precision Medicine

Adjuvant Alectinib for ALK+ NSCLC: An Interview with Dr. Benjamin Solomon

ALINA Trial Leads to New Treatment Option for Early-Stage ALK+ NSCLC

Could Precision Oncology Evolve to Treat Cancer Before It Develops?

Stark Contrast in Recent Tobacco Control Laws Worldwide

Mounting Evidence Supporting Neoadjuvant ChemoIO Means Surgeons Must Adapt

More Than Ever, Surgeons Must Collaborate to Ensure Patients Receive Appropriate Care

A New Treatment Option for Early-Stage ALK+ NSCLC: Adjuvant Alectinib

European Commission OKs Tislelizumab for NSCLC

In Case You Missed It: Recent News from IASLC